Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells
AssigneeCellular Sciences, Inc.
InventorAlain Martin
Life of this patent
Estimating the term…
Abstract
The present invention provides novel methods for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of an inflammatory agent in mammalian cells comprising contacting the mammalian cells with a therapeutically effective amount of an inflammatory regulator, wherein the inflammatory agent is selected from the group consisting of cytokines, transforming growth factor-β, elastase, and white blood cells, and wherein the inflammatory regulator is selected from the group consisting of pyruvates and pyruvate precursors.
Claims9
A method for treating a pulmonary disease state in a mammal, said disease state characterized by abnormally low levels of inflammatory agents in the mammalian cells, said method comprising:
- contacting the mammalian cells with an inflammatory regulator in an amount effective to up regulate the indigenous in vivo levels of an inflammatory agent in said cells;
- wherein said inflammatory regulator comprises a mixture of (i) pyruvate, a pyruvate precursor, or salts thereof, and (ii) α-keto-isovaleric acid, a precursor of α-keto-isovaleric acid, or salts thereof;
- and
- wherein said inflammatory agents are selected from the group consisting of elastase, white blood cells and cytokines selected from the group consisting of interleukin-6, interleukin-8, interleukin-10, interleukin-17, interleukin-23 and tumor necrosis factor-α.
Dependencies are inferred from the claim text.